Dr. Patricia Alred joins Asymchem Board of Scientific Advisors

TIANJIN, China, April 1, 2019 /PRNewswire/ -- Asymchem, a leading CDMO of Intermediates and API's for the pharmaceutical industry, today announced that Dr. Patricia A. Alred has joined the Asymchem Board of Scientific Advisors (BSA). Dr. Alred joins Professors Barry Sharpless, Phil Baran, Stephen Buchwald and others currently on the advisory board.

Patricia A. Alred received her Ph.D. in Biochemistry from the University of Lund in 1993, before continuing her post doc in chemical engineering at MIT. Dr. Alred's vast experience in the operations and development of Biomolecules came from years in leading roles, including Global Head of API Large Molecules at Johnson & Johnson, Ethicon VP of Operations, as well as GM of Janssen's Malvern Operations. She oversaw responsibility for all aspects of the product development cycle, including development and commercialization, supporting BLA/MAA applications. She played key roles in product manufacturing operation and facilities, in particular maintaining quality throughout the manufacturing process.

Dr. Alred was formerly a member of Janssen Pharmaceutical Development's Scientific Advisory Board, Janssen Commercial Manufacturing's Janssen Pharmaceutical Manufacturing Board, and Ethicon Biosurgery's Board.

The BSA was established in June 2013 and consists of 11 academic and industry technical leaders to provide valuable advice on research targets as well as up-to-date technologies with potential applications into the CDMO space. Collaborative research opportunities have continued to yield publications in JOC, JACS, OPRD, Science and others.

About Asymchem

Asymchem is a full-service CMC CDMO of API's for the global pharmaceutical industry, providing compliant and sustainable manufacturing solutions worldwide over the lifecycle of a drug. Capabilities include dedicated HPAPI, in-house enzyme evolution and fermentation for biotransformations, end-to-end continuous flow development and application, hydrogenation, cryogenic capabilities, dedicated carbapenem manufacture, and others. Founded in 1997, Asymchem employs 3820 personnel within China over 6 manufacturing sites. The company has been USFDA, TGA, CFDA and MFDS inspected.

SOURCE Asymchem

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED